-1753895653633.webp&w=3840&q=75)
2025 NOSCM | Follicular NHL: Novel Treatment Paradigms
Overview
Dr. Nakhle Saba discussed advances in follicular lymphoma, noting BR's superiority over R-CHOP and R-Squared, and benefits of maintenance rituximab. IN-MIND and L-TAF-R trials showed strong results with tafasitamab regimens. Promising therapies include EZH2 inhibitors, bispecifics, and BTK inhibitor nemtabrutinib.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Nakhle Saba, MD
Date of Release
July 30th, 2025
-1753895561853.webp&w=3840&q=75)
-1753895472875.webp&w=3840&q=75)